7.4 Pharmacoeconomics

Why Pharmacoeconomics Matters

Pharmacoeconomics is the application of economic methods to pharmaceutical products and services, balancing clinical and economic outcomes. It is essential to P&T committee decisions, formulary management, clinical pathway design, and health policy. With US drug spend exceeding $600 billion annually, payers and providers rely on pharmacoeconomic evidence to allocate scarce resources and demonstrate the value of new therapies.

The Four Methods

Cost-Minimization Analysis (CMA)

CMA is the simplest method. It assumes that the alternatives being compared have clinically equivalent outcomes (efficacy, safety, adherence). Only costs are compared. Example: two generic formulations of the same drug with documented bioequivalence — the lower-cost option dominates. CMA is inappropriate when outcomes differ in any clinically meaningful way.

Cost-Effectiveness Analysis (CEA)

CEA compares alternatives whose outcomes differ but can be measured on a common natural unit — cases prevented, mmHg reduced, life-years gained. The Incremental Cost-Effectiveness Ratio (ICER) is:

ICER = (Cost_A - Cost_B) / (Effect_A - Effect_B)

The ICER expresses the additional cost per additional unit of effect of one strategy over another. Example: a new statin costs $1,200 more per year and prevents 0.04 additional myocardial infarctions, giving ICER = $30,000 per MI prevented. ICER is interpreted against a willingness-to-pay (WTP) threshold — commonly $50,000 to $150,000 per QALY in the US, and 20,000 to 30,000 pounds per QALY under NICE in the UK.

Cost-Utility Analysis (CUA)

CUA is a special case of CEA using Quality-Adjusted Life Years (QALYs). A QALY combines survival and quality of life: one year in perfect health equals 1.0 QALY, while one year at 50% utility equals 0.5 QALY. Utilities are typically obtained from instruments such as the EQ-5D, SF-6D, or Health Utilities Index (HUI), often via time-tradeoff or standard-gamble methods. CUA enables comparisons across different diseases and interventions and is the most widely used method for health technology assessment. The result is reported as $/QALY.

Cost-Benefit Analysis (CBA)

CBA values outcomes in monetary terms (willingness to pay, human capital approach, cost of illness) and computes a Benefit-Cost Ratio (BCR):

BCR = Total Benefits (in $) / Total Costs (in $)

A BCR greater than 1 indicates the intervention is economically worthwhile. CBA is rarely used in pharmacy because monetizing health outcomes (such as a life saved) is ethically and methodologically difficult, but it is valuable when comparing health and non-health programs in a single analysis.

Perspective

The perspective of an analysis determines which costs and outcomes are included:

• Payer (insurer, PBM) — drug cost, medical cost, allowed amounts.
• Provider (hospital, health system) — acquisition cost, labor, overhead.
• Patient — copay, coinsurance, lost wages, transportation.
• Societal — all costs and benefits regardless of who pays or receives; preferred by the US Second Panel on Cost-Effectiveness in Health and Medicine.

Cost Types and Humanistic Outcomes

Direct medical costs include drugs, physician visits, hospitalizations, and lab tests. Direct non-medical costs include transportation, caregiver time, and lodging for treatment. Indirect costs capture productivity loss — absenteeism, presenteeism, and premature mortality valued via the human capital or friction-cost approach. Intangible costs reflect pain, suffering, and anxiety and are difficult to measure; they are sometimes monetized in CBA.

Humanistic outcomes include quality of life (QoL), patient satisfaction, and patient-reported outcomes (PROs). PRO instruments (for example, SF-36, EQ-5D, PROMIS, and disease-specific measures) capture the patient's experience through validated questionnaires. Humanistic outcomes are increasingly central to value-based contracts and FDA patient-focused drug development.

Application: P&T, Budget Impact, Discounting, and Sensitivity Analysis

Formulary and P&T Application

A Pharmacy and Therapeutics (P&T) committee reviews new drugs using monographs that integrate clinical evidence and pharmacoeconomic analysis. Decisions classify a drug as preferred, non-preferred, non-formulary, or restricted (prior authorization, step therapy, specialty-only). The economic evaluation is often CEA or budget impact analysis rather than CBA.

Budget Impact Analysis (BIA)

BIA estimates the financial impact of adopting a new drug on a payer's budget over a short time horizon (typically 1-3 years). Unlike CEA, BIA does not require outcomes to be valued — it forecasts total drug spend, plan migration, and per-member-per-month (PMPM) cost. BIA and CEA are complementary; payers use both to make adoption decisions.

Discounting

Future costs and outcomes are discounted to present value to account for time preference. The standard annual discount rate in the US is 3% per the Second Panel; historically both 3% and 5% have been used. Costs and outcomes occurring in different years should be discounted at the same rate for consistency.

Sensitivity Analysis

Sensitivity analysis tests how robust the conclusion is to uncertainty in inputs. Methods include:

• One-way (tornado diagram) — vary one parameter at a time.
• Two-way and multi-way — vary multiple parameters together.
• Probabilistic sensitivity analysis (PSA) — Monte Carlo simulation with distributions on all uncertain parameters; produces a cost-effectiveness acceptability curve (CEAC) showing the probability an intervention is cost-effective across WTP thresholds.

The Cost-Effectiveness Plane

The cost-effectiveness plane plots incremental cost on the y-axis against incremental effect on the x-axis, creating four quadrants:

• North-East (more costly, more effective) — ICER compared against the WTP threshold.
• South-East (less costly, more effective) — dominant; adopt regardless of WTP.
• South-West (less costly, less effective) — trade-off; depends on WTP and priorities.
• North-West (more costly, less effective) — dominated; reject.